The clinical relevance of MOG antibody testing in cerebrospinal fluid

Molly Reynolds; Irene Tan; Kristy Nguyen; Vera Merheb; Fiona X. Z. Lee; Benjamin P Trewin; Magdalena Lerch; Snehal Shah; Nigel Wolfe; Katherine Buzzard; Jeannette Lechner-Scott; Marzena Fabis-Pedrini; Anthony Fok; Nevin John; Chris Kneebone; Con Yiannikas; David A. Brown; Allan G. Kermode; Stephen Reddel; Russell C. Dale; Fabienne Brilot; Sudarshini Ramanathan; the Australasian MOGAD Study Group

doi:10.1002/acn3.52163

Back

The clinical relevance of MOG antibody testing in cerebrospinal fluid

Journal article

Open access

Peer reviewed

The clinical relevance of MOG antibody testing in cerebrospinal fluid

Molly Reynolds, Irene Tan, Kristy Nguyen, Vera Merheb, Fiona X. Z. Lee, Benjamin P Trewin, Magdalena Lerch, Snehal Shah, Nigel Wolfe, Katherine Buzzard, …

Annals of clinical and translational neurology, Vol.11(9), pp.2514-2519

2024

DOI: https://doi.org/10.1002/acn3.52163

Files and links (1)

pdf

Published583.69 kBDownload View

CC BY V4.0, Open Access

Abstract

Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is diagnosed by serum MOG‐immunoglobulin G (MOG‐IgG) in association with typical demyelination. 111/1127 patients with paired CSF/serum samples were seropositive for MOG‐IgG. Only 7/1016 (0.7%) seronegative patients had CSF‐restricted MOG‐IgG. While 3/7 patients had longitudinally extensive transverse myelitis, four had a confirmed alternate diagnosis (three multiple sclerosis, one CNS vasculitis). In a national referral setting, CSF‐restricted MOG‐IgG had a low sensitivity (2.63%, 95%CI 0.55–7.50%) and low positive predictive value (1.97%, 95%CI 0.45–8.13%). We strongly recommend serum as the preferred diagnostic biospecimen, and urge caution in the interpretation of CSF‐restricted MOG‐IgG in patients without clinico‐radiological features consistent with MOGAD.

Details

Title: The clinical relevance of MOG antibody testing in cerebrospinal fluid
Authors/Creators: Molly Reynolds - The University of Sydney
Irene Tan - Concord Repatriation General Hospital
Kristy Nguyen - Children's Hospital at Westmead
Vera Merheb - Children's Hospital at Westmead
Fiona X. Z. Lee - Children's Hospital at Westmead
Benjamin P Trewin - The University of Sydney
Magdalena Lerch - The University of Sydney
Snehal Shah - Princess Margaret Hospital for Children
Nigel Wolfe - Blacktown & Mount Druitt Hospital
Katherine Buzzard - The Royal Melbourne Hospital
Jeannette Lechner-Scott - John Hunter Hospital
Marzena Fabis-Pedrini - Perron Institute for Neurological and Translational Science
Anthony Fok - Monash Health
Nevin John - Monash Medical Centre
Chris Kneebone - Townsville Hospital
Con Yiannikas - The University of Sydney
David A. Brown - The University of Sydney
Allan G. Kermode - Murdoch University, Institute for Immunology and Infectious Diseases
Stephen Reddel - The University of Sydney
Russell C. Dale - The University of Sydney
Fabienne Brilot - The University of Sydney
Sudarshini Ramanathan - The University of Sydney
the Australasian MOGAD Study Group
Publication Details: Annals of clinical and translational neurology, Vol.11(9), pp.2514-2519
Publisher: Wiley Periodicals LLC on behalf of American Neurological Association
Identifiers: 991005691069207891
Copyright: © 2024 The Author(s).
Murdoch Affiliation: Centre for Molecular Medicine and Innovative Therapeutics
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Metrics

180 File views/ downloads

34 Record Views

10 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.203 Neuromuscular Disorders; 1.203.147 Multiple Sclerosis
Web Of Science research areas: Clinical Neurology; Neurosciences
ESI research areas: Neuroscience & Behavior